Suppr超能文献

妊娠早期血清可溶性血管内皮生长因子受体-1与子痫前期或胎儿生长受限结局的关系

Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation.

作者信息

Wathén Katja-Anneli, Tuutti Eija, Stenman Ulf-Håkan, Alfthan Henrik, Halmesmäki Erja, Finne Patrik, Ylikorkala Olavi, Vuorela Piia

机构信息

Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Biomedicum Helsinki, 00029 HUS, Helsinki, Finland.

出版信息

J Clin Endocrinol Metab. 2006 Jan;91(1):180-4. doi: 10.1210/jc.2005-1076. Epub 2005 Nov 1.

Abstract

CONTEXT

Vascular endothelial growth factor (VEGF) promotes placental vascularization, which is inadequate in preeclampsia and intrauterine growth retardation (IUGR). The soluble receptor of VEGF (sVEGFR-1), also known as soluble fms-like tyrosine kinase-1, is produced in the placenta and reduces VEGF activity. Therefore, elevated sVEGFR-1 could contribute to the development of preeclampsia and IUGR.

OBJECTIVE

The objective of this study was to study maternal serum sVEGFR-1 concentration in early pregnancy ending in preeclampsia and IUGR.

DESIGN

This was a case-control study.

SETTING

This study was conducted at Helsinki University Central Hospital (Helsinki, Finland), a tertiary referral center.

PATIENTS

Patients included 124 pregnant women, of whom 49 developed preeclampsia, 16 gave birth to IUGR infants without preeclampsia, and 59 remained normotensive and gave birth to normal-sized infants. Serum samples were collected at 12-15 and 16-20 gestational weeks.

MAIN OUTCOME MEASURES

Serum sVEGFR-1 concentrations were determined by ELISA.

RESULTS

Women with subsequent preeclampsia had higher [median; interquartile range (IQR)] concentrations of sVEGFR-1 at 16-20 wk gestation (436 and 282-699 ng/liter; P = 0.005) than the controls (296 and 184-508 ng/liter). The conclusion was the same if women with mild (340 and 285-750 ng/liter; P = 0.043) or severe (497 and 235-699 ng/liter; P = 0.022) preeclampsia were analyzed separately. An elevated sVEGFR-1 concentration at 16-20 wk gestation is associated with an increased risk of preeclampsia but not of isolated IUGR. Soluble VEGFR-1 concentration decreased by 15% from the first to the second sampling in the controls but not in women with preeclampsia or IUGR.

CONCLUSION

Elevated sVEGFR-1 concentrations at 16-20 wk gestation precede the clinical manifestations of preeclampsia. By neutralizing VEGF, sVEGFR-1 may contribute to inadequate placental vascularization.

摘要

背景

血管内皮生长因子(VEGF)可促进胎盘血管形成,而子痫前期和胎儿宫内生长受限(IUGR)时胎盘血管形成不足。VEGF的可溶性受体(sVEGFR-1),也称为可溶性fms样酪氨酸激酶-1,在胎盘中产生并降低VEGF活性。因此,sVEGFR-1升高可能导致子痫前期和IUGR的发生。

目的

本研究旨在探讨孕早期发生子痫前期和IUGR的孕妇血清sVEGFR-1浓度。

设计

这是一项病例对照研究。

地点

本研究在三级转诊中心赫尔辛基大学中心医院(芬兰赫尔辛基)进行。

患者

患者包括124名孕妇,其中49名发生子痫前期,16名分娩IUGR婴儿但无子痫前期,59名血压正常并分娩正常大小婴儿。在妊娠12 - 15周和16 - 20周时采集血清样本。

主要观察指标

采用酶联免疫吸附测定法(ELISA)测定血清sVEGFR-1浓度。

结果

随后发生子痫前期的孕妇在妊娠16 - 20周时sVEGFR-1浓度[中位数;四分位间距(IQR)]高于对照组(436和282 - 699 ng/升;P = 0.005)(296和184 - 508 ng/升)。若分别分析轻度(3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验